{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:08:05Z","timestamp":1789034885705,"version":"build-2803163510"},"reference-count":38,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Xunta de Galicia, Industrial Doctorate Programme","award":["09_IN606D_2021_2602026"],"award-info":[{"award-number":["09_IN606D_2021_2602026"]}]},{"DOI":"10.13039\/501100011033","name":"Agencia Estatal de Investigaci\u00f3n (AEI), Ministerio de Ciencia, Innovaci\u00f3n y Universidades (Spain), through the Torres Quevedo Programme","doi-asserted-by":"publisher","award":["PTQ2022-012497"],"award-info":[{"award-number":["PTQ2022-012497"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Despite the rapid expansion of targeted protein degradation (TPD), early characterization of PROTACs and molecular glues still relies predominantly on cellular degradation assays, making it difficult to determine whether poor degradation results from suboptimal E3 ligase engagement or from subsequent steps in the degradation mechanism. Moreover, productive degradation depends on balanced binary interactions, as both insufficient and excessively strong binding to either the E3 ligase or the protein of interest (POI) can impair degrader activity. Here, we report robust fluorescence polarization (FP) assays for the quantitative determination of ligand binding to the two most widely exploited E3 ligases, cereblon (CRBN) and von Hippel\u2013Lindau (VHL). Using proprietary fluorescent tracers, the assays were validated with chemically diverse molecular glues, clinically relevant PROTACs, and canonical ligands, yielding affinity values in excellent agreement with published data. Both assays were successfully miniaturized to 384-well format while maintaining analytical performance and subsequently implemented in standardized ready-to-use formats, facilitating reproducible affinity measurements across laboratories. These assays establish a rapid and accessible binding-first platform that complements cellular degradation studies; supports rational degrader discovery, profiling, and optimization; and enables the identification of structurally novel E3 ligase recruiters.<\/jats:p>","DOI":"10.3390\/ijms27188054","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:03Z","timestamp":1789031583000},"page":"8054","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bridging E3 Ligase Binding and Targeted Degradation Through Fluorescence Polarization"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3016-3113","authenticated-orcid":false,"given":"Luc\u00eda","family":"Gonz\u00e1lez-Pico","sequence":"first","affiliation":[{"name":"Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"},{"name":"Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Camino","sequence":"additional","affiliation":[{"name":"Celtarys Research SL, Avenida de Barcelona 7, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ortigueira","sequence":"additional","affiliation":[{"name":"Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"},{"name":"Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2539-3106","authenticated-orcid":false,"given":"Rub\u00e9n","family":"Prieto-D\u00edaz","sequence":"additional","affiliation":[{"name":"Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"},{"name":"Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5571-2812","authenticated-orcid":false,"given":"Eddy","family":"Sotelo","sequence":"additional","affiliation":[{"name":"Center for Research in Biological Chemistry and Molecular Materials (CIQUS), University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"},{"name":"Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3490-7703","authenticated-orcid":false,"given":"Maria","family":"Majellaro","sequence":"additional","affiliation":[{"name":"Celtarys Research SL, Avenida de Barcelona 7, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: Chimeric Molecules That Target Proteins to the Skp1\u2013Cullin\u2013F Box Complex for Ubiquitination and Degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","article-title":"Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4\/6 or PI3K\/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models","volume":"30","author":"Gough","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_3","unstructured":"Center for Drug Evaluation and Research (CDER) (2026). FDA Approves Vepdegestrant for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-025-01316-z","article-title":"Induced Proximity-Based Therapeutic Modalities","volume":"25","author":"King","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC Targeted Protein Degraders: The Past Is Prologue","volume":"21","author":"Langley","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1101\/gad.352916.125","article-title":"Combinatorial Use of VHL and KEAP1 PROTACs Reveals Unexpected Synergy and Hook Effect Relief","volume":"40","author":"Islam","year":"2026","journal-title":"Genes. Dev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/leu.2009.236","article-title":"Mechanism of Action of Immunomodulatory Drugs (IMiDS) in Multiple Myeloma","volume":"24","author":"Quach","year":"2010","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1039\/D2CB00207H","article-title":"Protein\u2013Protein Interfaces in Molecular Glue-Induced Ternary Complexes: Classification, Characterization, and Prediction","volume":"4","author":"Rui","year":"2023","journal-title":"RSC Chem. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","article-title":"Iberdomide (CC-220) Is a Potent Cereblon E3 Ligase Modulator with Antitumor and Immunostimulatory Activities in Lenalidomide- and Pomalidomide-Resistant Multiple Myeloma Cells with Dysregulated CRBN","volume":"34","author":"Bjorklund","year":"2020","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature18611","article-title":"A Novel Cereblon Modulator Recruits GSPT1 to the CRL4CRBN Ubiquitin Ligase","volume":"535","author":"Matyskiela","year":"2016","journal-title":"Nature"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1177\/2472555220965528","article-title":"E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones","volume":"26","author":"Ishida","year":"2021","journal-title":"SLAS Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s42004-025-01598-9","article-title":"Synthesis, Biological Evaluation and Clinical Trials of Cereblon-Based PROTACs","volume":"8","author":"Vicente","year":"2025","journal-title":"Commun. Chem."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Stover, E. (2026). A Phase 1b Study of BCL-XL Degrader DT2216 in Combination with Weekly Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer.","DOI":"10.1158\/1535-7163.TARG-25-B004"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1021\/acs.jmedchem.8b01413","article-title":"Iterative Design and Optimization of Initially Inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a Potent, Fast, and Selective von Hippel\u2013Lindau (VHL) Based Dual Degrader Probe of BRD9 and BRD7","volume":"62","author":"Zoppi","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2174\/138161209787315594","article-title":"Designing Multiple Ligands\u2014Medicinal Chemistry Strategies and Challenges","volume":"15","author":"Morphy","year":"2009","journal-title":"Curr. Pharm. Des."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.4155\/fmc-2020-0073","article-title":"Assays and Technologies for Developing Proteolysis Targeting Chimera Degraders","volume":"12","author":"Liu","year":"2020","journal-title":"Future Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1038\/s41467-023-39904-5","article-title":"Affinity and Cooperativity Modulate Ternary Complex Formation to Drive Targeted Protein Degradation","volume":"14","author":"Wurz","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.chembiol.2024.01.003","article-title":"The Cyclimids: Degron-Inspired Cereblon Binders for Targeted Protein Degradation","volume":"31","author":"Ichikawa","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1042\/BCJ20243018","article-title":"Methods to Accelerate PROTAC Drug Discovery","volume":"482","author":"Osman","year":"2025","journal-title":"Biochem. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.tibs.2026.07.004","article-title":"Linkerology in PROTACs: Learnings for Proximity-Inducing Therapeutics","volume":"51","author":"Urbina","year":"2026","journal-title":"Trends Biochem. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"6648","DOI":"10.1021\/acs.jmedchem.9b01928","article-title":"Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma","volume":"63","author":"Hansen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1021\/acs.jmedchem.6b01921","article-title":"A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos","volume":"61","author":"Matyskiela","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1\u2013CRBN E3 Ubiquitin Ligase in Complex with Thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Henderson, J.A., Eron, S.J., Good, A., Kirby, R.J., Perino, S., Agafonov, R.V., Chaturvedi, P., Class, B., Cocozziello, D., and Hart, A.A. (2022). Abstract ND13: The Discovery and Characterization of CFT7455: A Potent and Selective Degrader of IKZF1\/3 for the Treatment of Relapsed\/Refractory Multiple Myeloma. Cancer Res., 82.","DOI":"10.1158\/1538-7445.AM2022-ND13"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1107\/S2059798322000092","article-title":"High-Resolution Structures of the Bound Effectors Avadomide (CC-122) and Iberdomide (CC-220) Highlight Advantages and Limitations of the MsCI4 Soaking System","volume":"78","author":"Heim","year":"2022","journal-title":"Acta Crystallogr. Sect. D"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1021\/acsmedchemlett.1c00475","article-title":"Physicochemistry of Cereblon Modulating Drugs Determines Pharmacokinetics and Disposition","volume":"12","author":"Kong","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"eaat0572","DOI":"10.1126\/science.aat0572","article-title":"Defining the Human C2H2 Zinc Finger Degrome Targeted by Thalidomide Analogs through CRBN","volume":"362","author":"Sievers","year":"2018","journal-title":"Science"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.32604\/or.2025.065123","article-title":"Discovery and Characterization of Novel IKZF1\/3 Glue Degraders against Multiple Hematological Cancer Cell Lines","volume":"33","author":"Wei","year":"2025","journal-title":"Oncol. Res."},{"key":"ref_31","unstructured":"Revvity (2023). Biochemical and Cell-Based No-Wash Platform to Uncover the Full Potential of PROTAC\u00ae, Revvity."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1182\/blood-2021-147473","article-title":"Nx-5948, a Selective Degrader of BTK with Activity in Preclinical Models of Hematologic and Brain Malignancies","volume":"138","author":"Robbins","year":"2021","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1158\/0008-5472.CAN-25-1301","article-title":"CFT1946 Is an Orally Available Brain-Penetrant BRAFV600-Mutant Degrader That Overcomes BRAF Inhibitor Resistance","volume":"86","author":"Kreger","year":"2026","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Liang, Y., Sowa, M.E., Jackson, K.L., Simard, J.R., Kreger, B., Li, P., Poling, L., Baddour, J., Good, A., and Huang, H. (2023). Abstract ND05: The Discovery and Characterization of CFT1946: A Potent, Selective, and Orally Bioavailable Degrader of Mutant BRAF for the Treatment of BRAF-Driven Cancers. Cancer Res., 83.","DOI":"10.1158\/1538-7445.AM2023-ND05"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41589-018-0055-y","article-title":"Plasticity in Binding Confers Selectivity in Ligand-Induced Protein Degradation","volume":"14","author":"Nowak","year":"2018","journal-title":"Nat. Chem. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13312","DOI":"10.1038\/ncomms13312","article-title":"Potent and Selective Chemical Probe of Hypoxic Signalling Downstream of HIF-\u03b1 Hydroxylation via VHL Inhibition","volume":"7","author":"Frost","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1038\/s41589-025-01936-x","article-title":"A Small-Molecule VHL Molecular Glue Degrader for Cysteine Dioxygenase 1","volume":"21","author":"Tutter","year":"2025","journal-title":"Nat. Chem. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8054\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:19:13Z","timestamp":1789031953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/18\/8054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":38,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27188054"],"URL":"https:\/\/doi.org\/10.3390\/ijms27188054","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]}}}